Pulmonary arterial hypertension
Conditions
Interventions
Treatment with sildenafil 25mg three times daily for 24 weeks
Treatment with prior therapy without sildenafil for 24 weeks
Sponsors
Division of cardiovascular internal medicine, The University of Tokyo Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with pulmonary arterial hypertension 2. Patients in WHO functional class II-IV and with estimated right ventricular systolic pressure (transtricuspid valve pressure gradient+10)>40mmHg under prior therapy 3. Patients with informed concent
Exclusion criteria
Exclusion criteria: 1. Patients with PCWP>15mmHg 2. Pregnat women or women of childbearing potential or brestfeeding 3. Patients who are being treated with medicines that contain nitrates 4. Patients who are being treated with phosphodiesterase inhibitors other than sildenafil 5. Patients who are otherwise judged inappropriate for inclusion in the study by the investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Decrease in pulmonary arterial pressure, pulmonary vascular resistance and increase in cardiac output at 24 weeks after allocation of patients | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement of exercise tolerance (anaerobic threshold and peak VO2) assessed by cardiopulmonary exercise testing | — |
Countries
Japan
Contacts
Public ContactAtsushi Yao
The University of Tokyo Hospital Division of cardiovascular internal medicine
Outcome results
None listed